Shaorong G. Yu
Nanjing, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 50 publications
HHLA2 promotes immune evasion in EGFR-mutant lung cancer by inhibiting CD8+ T cell glutamine metabolism via KIR3DL3 interaction.
Journal: Cancer letters
Published: September 10, 2025
Aspergillus fumigatus promotes tumor angiogenesis via SLC7A11 on myeloid-derived suppressor cells.
Journal: EMBO reports
Published: January 15, 2025
Induction Immunochemotherapy Followed by Hypo-Fractionated Radiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer.
Journal: Clinical lung cancer
Published: October 21, 2024
Comparison of camrelizumab, pembrolizumab, tislelizumab, and sintilimab as first-line treatment in patients with non-small cell lung cancer: a retrospective study.
Journal: Journal of thoracic disease
Published: September 08, 2024
Targeting PAK1 suppresses tumor progression by promoting mRNA decay of oncogenic factors and enhancing chemotherapeutic efficacy in colorectal cancer.
Journal: Genes & diseases
Published: June 26, 2024
CircATXN7 regulates the proliferation and invasion of esophageal cancer cells through miR-4319/NLRC5.
Journal: Cellular signalling
Published: March 12, 2024
Comparison of Efficacy and Safety of Second-Line Treatment Options for Advanced Small-Cell Lung Cancer: A Retrospective Analysis.
Journal: Technology in cancer research & treatment
Published: January 23, 2024
Efficacy and safety analysis of immune checkpoint inhibitor rechallenge therapy in locally advanced and advanced non-small cell lung cancer: a retrospective study.
Journal: Journal of thoracic disease
Published: November 16, 2023
Comparison of Efficacy and Safety of First-Line Treatment Options for Unresectable Stage III Non-Small Cell Lung Cancer: A Retrospective Analysis.
Journal: International journal of clinical practice
Published: September 07, 2023
Comment on "Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial".
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: August 07, 2023
Anlotinib combined with whole-brain radiotherapy in non-small cell lung cancer with multiple brain metastases that progressed or developed after at least one lines of prior treatment.
Journal: Frontiers in oncology
Published: February 19, 2023
Efficacy and safety of bevacizumab biosimilar compared with reference bevacizumab in locally advanced and advanced non-small cell lung cancer patients: A retrospective study.
Journal: Frontiers in oncology
Published: September 05, 2022
Last Updated: 09/26/2026